BON Announces Unlocking Broccoli's Nutritional Power: Advanced Delivery System for Glucoraphanin Activation
Rhea-AI Summary
Bon Natural Life (Nasdaq: BON) has announced a breakthrough in broccoli-derived nutrition with their patent-pending Glucoraphanin-Myrosinase co-delivery system. This biotech innovation enhances the bio-activity of glucoraphanin, a key compound in broccoli that converts to sulforaphane.
The technology addresses the previously inefficient conversion process of glucoraphanin to sulforaphane, which is known for its anti-cancer, sleep improvement, neuroprotective, digestive enhancement, anti-inflammatory, antioxidant, and anti-aging properties. The company's solution ensures optimal enzymatic activation within the body, achieving higher conversion efficiency to bio-active sulforaphane.
The product is scheduled for market entry in Q2 2025, targeting the functional foods and beverages sector. The company positions this innovation as a potential catalyst for expanding the broccoli-derived wellness market, with applications across multiple sectors including anti-tumor therapies, mental health support, and digestive health management.
Positive
- Patent-pending technology addressing a significant market challenge
- Targeting multi-billion dollar market opportunity across multiple sectors
- Planned Q2 2025 market entry with clear commercialization timeline
- Enhanced bioavailability solving key industrial application challenge
Negative
- Product not yet commercialized - future market success uncertain
- No specific efficacy data or clinical validation metrics provided
News Market Reaction 1 Alert
On the day this news was published, BON declined 6.72%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
XI’AN, China, April 08, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced our biotech innovation addresses nutritional critical challenges through a patent-pending Glucoraphanin-Myrosinase co-delivery system that significantly enhances the bio-activity of glucoraph anin, a key bio-active compound in broccoli.
Broccoli stands as a nutrient-rich super food containing glucoraphanin-the vegetable's key bio-active compound that could metabolically converted into sulforaphane within biological systems. Sulforaphane is associated with diverse bio-active properties ranging from anti-cancer, sleep improvement, neuroprotection, digestive system enhancement, anti-inflammatory, antioxidant, and anti-aging effects. However, this precursor molecule requires enzymatic conversion to sulforaphane, the active form that delivers these effects. This biological conversion process proves challenging and inefficient, posing a significant obstacle to effective nutritional utilization and commercial application.
This breakthrough technology ensures optimal enzymatic activation within the body, achieving unprecedented conversion efficiency to bio-active sulforaphane. By industrially solving the fundamental bio-availability issue, we're positioned to revolutionize functional food applications. Driven by the compound’s diverse applications with significant potential in anti-tumor therapies, mental health support, and digestive health management, ongoing technological innovations—specifically those enhancing efficiency, usability, and user compliance—are expected to unlock a multi-billion-dollar for sulforaphane across emerging sectors.
Yongwei Hu, CEO & Chairman of Bon, stated,“scheduled for Q2 2025 market entry, this advancement promises to transform and notably broaden the broccoli-derived wellness market, particularly in functional foods and beverages. This innovation holds immense market potential and is poised to fuel significant industry expansion through its unique value proposition.”
About Bon Natural Life Limited ("BON")
BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company’s website at http://www.bnlus.com.
For more information, please contact:
Cindy Liu | IR
Email: bonnatural@appchem.cn
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes,""expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
FAQ
When will BON's new glucoraphanin delivery system launch?
What health benefits does BON's broccoli-derived compound target?
What problem does BON's new delivery system solve?
Which markets will BON's new glucoraphanin technology target?
